Merck's earnings call highlighted significant near-term headwinds due to the COVID-19 pandemic, impacting patient access to healthcare, particularly for physician-administered products.  Reduced hospital visits and social distancing measures are expected to affect sales, especially in the second quarter, which is anticipated to be the peak impact period. The company's strong financial position and focus on R&D and business development are expected to support long-term growth.
[0]
